MedTrace Logo

Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II

NCT00186043 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2017-09-27

Study results available
· View outcomes & findings →

Summary

1. The primary objective of this study is to examine the efficacy of quetiapine (Seroquel) in treatment of dysphoric hypomania in patients with Bipolar II disorder.
2. To evaluate the utility of Seroquel add-on treatment to decrease mixed depressive and hypomanic symptoms.

Conditions

  • Bipolar II Disorder

Interventions

DRUG

Quetiapine/Seroquel

Quetiapine/Seroquel

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Terence Ketter, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00186043 on ClinicalTrials.gov